PharmaCyte Biotech (PMCB) Income from Continuing Operations (2010 - 2026)
PharmaCyte Biotech (PMCB) reported Income from Continuing Operations of -$840,430 for fiscal Q1 2027 (quarter ended Jul 31, 2026), compared with -$630,512 a year earlier.
Powered by 
Analysis
PharmaCyte Biotech (PMCB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Over the twelve months ended Jul 31, 2026, PharmaCyte Biotech's Income from Continuing Operations came in at -$6.33 million; for FY2026 (ended Apr 30, 2026), it was -$6.12 million.
- By fiscal year, Income from Continuing Operations came in at -$2.96 million in FY2025, -$5.12 million in FY2024, -$4.52 million in FY2023 and -$4.23 million in FY2022.
- Five-year quarterly Income from Continuing Operations spans a low of -$2.43 million in fiscal Q4 2026 and a high of -$180,346 in fiscal Q4 2023.
- Per Business Quant data, the three fiscal quarters before Q1 2027 came in at -$2.43 million (Q4 2026), -$1.89 million (Q3 2026) and -$1.17 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,137.66 Bn | 1,106.24 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 636.13 Bn | 556.00 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 505.28 Bn | 478.39 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 358.10 Bn | 312.48 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 292.59 Bn | 256.58 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.81 Bn | 239.50 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.53 Bn | 192.93 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.17 Bn | 117.82 Bn | 10.94 Bn | -246.00 Mn |
| 10 | PharmaCyte Biotech | 3.87 Mn | -68.98 Mn | - | -840,430.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -840,430.00 |
| Apr 30, 2026 | -2.43 Mn |
| Jan 31, 2026 | -1.89 Mn |
| Oct 31, 2025 | -1.17 Mn |
| Jul 31, 2025 | -630,512.00 |
| Apr 30, 2025 | -811,989.00 |
| Jan 31, 2025 | -704,560.00 |
| Oct 31, 2024 | -723,498.00 |
| Jul 31, 2024 | -721,455.00 |
| Apr 30, 2024 | -2.42 Mn |
| Jan 31, 2024 | -987,284.00 |
| Oct 31, 2023 | -515,339.00 |
| Jul 31, 2023 | -1.20 Mn |
| Apr 30, 2023 | -180,346.00 |
| Jan 31, 2023 | -917,094.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.54 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -810,660.00 |
| Oct 31, 2021 | -979,266.00 |
API Access
PharmaCyte Biotech Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=PMCB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "PMCB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=PMCB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();